Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Administration of Dendritic Cells and Anti-PD-1 Antibody Converts X-ray Irradiated Tumors Into Effective In situ Vaccines.

Wang Y, Zenkoh J, Gerelchuluun A, Sun L, Cai S, Li X, Tsuboi K.

Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):958-969. doi: 10.1016/j.ijrobp.2018.11.019. Epub 2018 Nov 17.

PMID:
30458232
2.

Hyperfractionated high-dose proton beam radiotherapy for clival chordomas after surgical removal.

Hayashi Y, Mizumoto M, Akutsu H, Takano S, Matsumura A, Okumura T, Kawabe T, Zenkoh J, Sakurai H, Tsuboi K.

Br J Radiol. 2016 Jul;89(1063):20151051. doi: 10.1259/bjr.20151051. Epub 2016 Apr 21.

3.

 Generation of low-flux X-ray micro-planar beams and their biological effect on a murine subcutaneous tumor model.

Hong Z, Zenkoh J, Le B, Gerelchuluun A, Suzuki K, Moritake T, Washio M, Urakawa J, Tsuboi K.

J Radiat Res. 2015 Sep;56(5):768-76. doi: 10.1093/jrr/rrv037. Epub 2015 Jul 3.

4.

A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma.

Abei M, Okumura T, Fukuda K, Hashimoto T, Araki M, Ishige K, Hyodo I, Kanemoto A, Numajiri H, Mizumoto M, Sakae T, Sakurai H, Zenkoh J, Ariungerel G, Sogo Y, Ito A, Ohno T, Tsuboi K.

Radiat Oncol. 2013 Oct 16;8:239. doi: 10.1186/1748-717X-8-239.

5.

Celecoxib enhances radiosensitivity of hypoxic glioblastoma cells through endoplasmic reticulum stress.

Suzuki K, Gerelchuluun A, Hong Z, Sun L, Zenkoh J, Moritake T, Tsuboi K.

Neuro Oncol. 2013 Sep;15(9):1186-99. doi: 10.1093/neuonc/not062. Epub 2013 May 7.

6.

In vitro stemness characterization of radio-resistant clones isolated from a medulloblastoma cell line ONS-76.

Sun L, Moritake T, Zheng YW, Suzuki K, Gerelchuluun A, Hong Z, Zenkoh J, Taniguchi H, Tsuboi K.

J Radiat Res. 2013 Jan;54(1):61-9. doi: 10.1093/jrr/rrs078. Epub 2012 Sep 5.

7.

Nonpeptide mimic of bradykinin with long-acting properties.

Aramori I, Zenkoh J, Morikawa N, Asano M, Hatori C, Sawai H, Kayakiri H, Satoh S, Inoue T, Abe Y, Sawada Y, Mizutani T, Inamura N, Iwami M, Nakahara K, Kojo H, Oku T, Notsu Y.

Immunopharmacology. 1999 Dec;45(1-3):185-90.

PMID:
10615010
8.

Nonpeptide mimic of bradykinin with long-acting properties at the bradykinin B2 receptor.

Aramori I, Zenkoh J, Morikawa N, Asano M, Hatori C, Sawai H, Kayakiri H, Satoh S, Inoue T, Abe Y, Sawada Y, Mizutani T, Inamura N, Nakahara K, Kojo H, Oku T, Notsu Y.

Mol Pharmacol. 1997 Jul;52(1):16-20.

PMID:
9224807
9.

Novel subtype-selective nonpeptide bradykinin receptor antagonists FR167344 and FR173657.

Aramori I, Zenkoh J, Morikawa N, O'Donnell N, Asano M, Nakamura K, Iwami M, Kojo H, Notsu Y.

Mol Pharmacol. 1997 Feb;51(2):171-6.

PMID:
9203620
10.

Subtype- and species-selectivity of a tachykinin receptor antagonist, FK888, for cloned rat and human tachykinin receptors.

Aramori I, Morikawa N, Zenkoh J, O'Donnell N, Iwami M, Kojo H, Notsu Y, Okuhara M, Ono S, Nakanishi S.

Eur J Pharmacol. 1994 Oct 14;269(2):277-81.

PMID:
7531648

Supplemental Content

Loading ...
Support Center